A phase IV, placebo-controlled, randomised, double-blind, pilot study of the effects of prolonged-release fampridine as adjunct therapy in multiple sclerosis

Trial Profile

A phase IV, placebo-controlled, randomised, double-blind, pilot study of the effects of prolonged-release fampridine as adjunct therapy in multiple sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Sep 2016 Efficacy results (n=37) were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 09 Jun 2015 New trial record
    • 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top